![Francesca Chiodi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Postes actifs de Francesca Chiodi
Sociétés | Poste | Début | Fin |
---|---|---|---|
IMED AB
![]() IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | Directeur/Membre du Conseil | 26/11/2009 | - |
Fondateur | 26/11/2009 | - |
Historique de carrière de Francesca Chiodi
Statistiques
Internationale
Suède | 2 |
Opérationnelle
Director/Board Member | 1 |
Founder | 1 |
Sectorielle
Retail Trade | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
IMED AB
![]() IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | Retail Trade |
- Bourse
- Insiders
- Francesca Chiodi
- Expérience